Poly-MVA: What Is Actually in the Bottle, What the Research Shows, and How to Decide

Poly-MVA is a liquid supplement built on a palladium-lipoic acid complex, and it commonly sells for around $245 a bottle. Before you spend that, you deserve the one fact most pages about it bury or skip: there are no published human clinical trials of Poly-MVA. This guide lays out every study that does exist, labels each one by the model it used, reports the partial negative result that rarely appears in marketing, and then gives you an honest comparison to plain alpha-lipoic acid, which has real human trials and costs a fraction as much. The candor is the point.

• What Poly-MVA Actually Is
• What Is Actually in the Bottle
• Palladium, Explained
• What the Research Actually Shows
• The Comparison That Matters: Poly-MVA vs Plain Alpha-Lipoic Acid
• How Alpha-Lipoic Acid Products Differ
• Safety and Who Should Ask Their Doctor First
• How to Read the Label
• What Poly-MVA Is Not
• How to Decide
• What We Recommend
• References
• Frequently Asked Questions

What Poly-MVA Actually Is

Poly-MVA is a liquid dietary supplement built around a palladium-lipoic acid complex, abbreviated LAPd. The name expands to minerals, vitamins, and amino acids, which is where the letters M, V, and A come from. It is a red-brown liquid taken by mouth, and it was created by Merrill Garnett, described as a former dentist who later became a biochemist.

The core idea joins two things: a metal (palladium) and an antioxidant molecule (lipoic acid), fused into a single complex. Mechanistic claims in the literature describe LAPd as having greater redox potential than lipoic acid alone and as targeting mitochondrial complex I. That is the whole scientific story in one sentence. The product is trying to act on how cells make energy.

If you want the wider background on that topic, our guide to mitochondrial dysfunction and cellular energy covers how mitochondria fit into everyday health.

What Is Actually in the Bottle

Beyond the palladium-lipoic acid complex, the formula contains three familiar ingredients. These are the components you can actually see on a label and evaluate on their own terms:

• Alpha-lipoic acid, an antioxidant the body already uses as an enzyme cofactor.
• Acetylcysteine, a well-known antioxidant amino acid derivative.
• B vitamins.

So the bottle holds a novel mineral complex plus a supporting cast of ordinary, well-studied nutrients. The supporting cast is not what you are paying $245 for, and it is not what makes the product interesting. The differentiator is the palladium, which is also the part with the least human data behind it.

Palladium, Explained

Palladium is a platinum-group metal, and it is most familiar for its use in catalytic converters. Environmental exposure to it has risen as those devices have spread, and in one general-population survey it was detected in more than 90% of adults tested. That tells you something about the background, not about the supplement.

Here is the distinction that matters. The known toxicity research on palladium is about inhaled nanoparticles and occupational exposure, not about swallowing a palladium-lipoic acid complex. Reviews of palladium nanoparticles focus on lung cells, the endothelium, and blood, and on workplace risk. Palladium also appears on the list of metal allergens of growing significance, which is why a metal allergy is worth flagging.

What does not exist is a published human safety trial of an oral palladium-lipoic acid supplement. The specific safety profile of long-term ingestion is simply not established in the literature. That is not the same as calling it dangerous. It means no one has measured it. For context on how the body handles metals and antioxidants, see our page on detox and methylation.

What the Research Actually Shows

Start with the sentence that should have been on the marketing page all along. There are no published human clinical trials of Poly-MVA. Every study in the record is either in animals or in a dish. What follows is that entire list, with each study labeled by the model it used.

The animal studies

• Aged rat heart mitochondria. A 2009 study by Sudheesh and colleagues reported that daily Poly-MVA significantly enhanced Krebs cycle dehydrogenase activity and respiratory complexes I to IV in the heart of aged rats.
• Aged rat myocardial antioxidant status. A 2010 study by the same group found that glutathione rose and lipid peroxidation fell in aged rat heart mitochondria.
• Aged rat brain mitochondria. Ajith and colleagues studied energy metabolism in brain mitochondria of aged rats in 2014.
• Diabetic rats. A 2011 study reported that the palladium-lipoic acid complex attenuated alloxan-induced hyperglycemia and improved the declined blood antioxidant status in diabetic rats.
• Gerbils. Antonawich and colleagues gave gerbils saline or 30, 50, or 70 mg/kg of the complex every 24 hours after an induced occlusion, then assessed outcomes by nesting behavior and blinded measures.
• Mice and radiation. A 2010 study reported that oral dosing enhanced endogenous spleen colony formation in mice after gamma radiation.
• Mouse skin papilloma model. A 2017 study reported that Poly-MVA attenuated chemically initiated and promoted skin papilloma formation in mice.
• Radiotherapy adjunct in animals. A 2016 study examined the complex as an adjunct to radiotherapy in animals.

These are real findings, and some are genuinely interesting. None of them is a human result. A rat heart is not a human heart, and a mechanism observed in an animal does not tell you the size of any effect in a person. For the tissue-specific angles, our hubs on heart and circulation, brain and memory, and weight and metabolism cover the wider nutrient picture.

The partial null result you should know about

The most important study to report accurately is also the one you will almost never see in sales material. In 2017, Sridharan and colleagues gave Poly-MVA late in a rat model of radiation-induced heart disease. The complex modified cardiac mitochondria, but it did not modify the functional or structural manifestations of the condition in those animals.

Read that carefully. The mechanism moved. The outcome did not. This is a partial negative result, and it is exactly the kind of finding a page built only on enthusiasm would leave out.

The laboratory studies

Two more studies were done in a dish rather than in a living animal. A 2009 paper characterized how the lipoic acid-palladium complex interacts with double-stranded DNA, including the supplement itself, using voltammetry and atomic force microscopy. A 2021 study looked at the radioprotective effect of a palladium alpha-lipoic acid nano-complex on hemoglobin, using blood from male rats.

In vitro work is where a mechanism gets explored, and it is a long way from a person taking a supplement. The full evidence base is animal and laboratory work, and nothing more.

What reference sources say

Wikipedia describes Poly-MVA as an "unproven alternative cancer treatment" and states that there is no medical evidence of a health benefit, with concern that using it alongside standard treatment could reduce that treatment's effectiveness. That is Wikipedia's characterization, and it is reported here as such. Wikipedia also notes that the product has been marketed for a range of serious conditions using customer testimonials.

For market context, Wikipedia records that a year's supply was reported to cost US$19,800 in 2004, a historical figure rather than today's price. In 2005 the treatment was listed among ineffective alternatives sold by clinics in and around Tijuana, Mexico, though the source carries its own caveat that the material was not specific to Poly-MVA. None of this is a verdict from the research literature. It is the public record around the product, and it belongs in an honest assessment.

The Comparison That Matters: Poly-MVA vs Plain Alpha-Lipoic Acid

Here is the most useful thing this page can do for you. Plain alpha-lipoic acid, the ordinary supplement you can buy for a few dollars, has actual human trials behind it. Poly-MVA does not.

The classic trials are known by name:

• ALADIN, a three-week multicenter randomized controlled trial published in 1995.
• ALADIN II, a two-year multicenter randomized double-blind placebo-controlled trial published in 1999.
• ALADIN III, a seven-month multicenter randomized trial published in 1999.
• SYDNEY 2, published in 2006, which evaluated oral alpha-lipoic acid in adults.

These trials are not perfect. Oral alpha-lipoic acid research also includes a 2020 randomized double-blinded placebo-controlled study, and the honest observation that most human studies of this molecule have been of limited quality. But they exist, they are in people, and they are the real benchmark. If you want the full picture, our alpha-lipoic acid benefits guide goes deeper. A standard product such as Pure Encapsulations Alpha Lipoic Acid 400 mg is one way to buy the molecule behind that record.

The line that decides it: the palladium complex has an interesting animal and laboratory story and no human trial record. Plain alpha-lipoic acid has a real, if modest, human trial record at a fraction of the cost. Both statements are true at once, and a buyer deserves both.

How Alpha-Lipoic Acid Products Differ

Choosing an alpha-lipoic acid product is not as simple as grabbing any bottle, because the forms are not interchangeable. Three facts explain why. You can see part of the difference on a label: a product that states a defined per-capsule dose gives you the first thing worth comparing.

Only one form occurs in nature

Lipoic acid is an organosulfur compound derived from caprylic acid, built around a 1,2-dithiolane ring. It is a cofactor for five enzyme systems, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Only the (R)-(+)-enantiomer, called RLA, occurs in nature. Chemical synthesis produces a 50/50 mixture of the R and S forms, and the S form shows lower activity and may competitively interfere with RLA.

Absorption is limited and food changes it

Oral bioavailability of alpha-lipoic acid is listed at about 30%, limited by reduced solubility, a lack of stability in the stomach, and first-pass metabolism in the liver. Absorption falls when you take it with food. The practical guidance is to dose 30 to 60 minutes before a meal or at least 120 minutes after one.

The R form has its own behavior

Pharmacokinetic studies in healthy volunteers have measured how the racemic mix behaves after single oral doses, and separate work has examined the bioavailability of an R-alpha-lipoic acid complex. Different forms, different behavior. If you compare products, compare the form and the dose, not just the milligrams.

Safety and Who Should Ask Their Doctor First

Alpha-lipoic acid has a longer human safety record than the palladium complex, partly because Germany has approved it as a drug since 1966. Poly-MVA does not share that history.

We are not going to pretend the palladium question is settled, because it is not. The safety literature covers inhaled particles and workplace exposure. It does not cover a supplement swallowed daily for months.

Talk to your prescriber or pharmacist first if any of these apply to you:

• You have a known metal allergy, since palladium is a recognized metal allergen.
• You are pregnant or breastfeeding.
• You take prescription medication of any kind, so interactions can be checked.
• You are managing a health condition with a clinician's guidance.

This is not a scare tactic. It is what any careful practitioner would say about a compound whose long-term oral use has never been formally studied in people.

How to Read the Label

If you decide to evaluate either product, the label is where you start. A few things are worth checking every time.

1. The form. For alpha-lipoic acid, look for whether it is the R form, the racemic mix, or an R-complex. They are not equivalent.
2. The dose per serving. Know how many milligrams you get per capsule or per dose, so you can compare cost per day rather than cost per bottle.
3. The full ingredient list. For Poly-MVA, confirm what is in the bottle beyond the complex, which is the alpha-lipoic acid, acetylcysteine, and B vitamins described above.
4. The serving size. A large serving that empties the bottle quickly can make a low sticker price expensive in practice.

Cost per day is the number that matters, not cost per bottle. Poly-MVA is commonly listed at roughly $245 for an eight-ounce bottle, and the historical 2004 figure of $19,800 for a year's supply shows how high this category has been priced before. Compare that daily number against a plain alpha-lipoic acid product before you decide what the premium buys.

What Poly-MVA Is Not

It is worth stating plainly what this article is not claiming, because the gap between the marketing and the evidence is where buyers get hurt.

• Poly-MVA is not backed by human clinical trials. None exist in the published record.
• It is not a substitute for standard medical care, and Wikipedia notes concern that combining it with standard treatment could reduce that treatment's effectiveness.
• It is not the same molecule as plain alpha-lipoic acid, even though lipoic acid is part of it.
• Its long-term safety in humans has not been established.

None of this is an attack on the manufacturer. Poly-MVA is made by Amarc Enterprises, and grading the evidence is not the same as disparaging the company that makes a product. A supplement can be made in good faith and still be ahead of its own evidence. That is the whole story here.

How to Decide

If you have read this far, you can make the call with clear eyes. Three honest paths:

1. If human trial data is your line, plain alpha-lipoic acid clears it and Poly-MVA does not. Start there.
2. If you want the palladium complex specifically, know that you are paying for a mechanism, not an outcome, and an approximately $245 bottle is a real premium over that mechanism's plain cousin.
3. If you are working with a practitioner, that conversation should come before the purchase, not after.

Agape Nutrition carries practitioner-grade products across the categories this topic touches most. Whatever you choose, choose it because you understood the evidence, not because the page you landed on never showed it to you.

What We Recommend

Agape Nutrition stocks both sides of the comparison in this guide, and the prices below are current. To be explicit: the two Poly-MVA products below have no human clinical trial data behind them, and listing them here is not an efficacy claim for any outcome.

• Amarc Enterprises, Poly-MVA Lipoic Acid Mineral Complex, 8 fl oz (236 ml) ($245.00): the palladium-lipoic acid complex this guide is about, a red-brown liquid taken by mouth in the amounts the label gives.
• Amarc Enterprises, Poly-MVA Lipoic Acid Mineral Complex, 4 fl oz (118 ml) ($130.00): the same palladium-lipoic acid complex in a smaller bottle, for trying it without the larger commitment.
• DaVinci Labs, Alpha Lipoic Acid 300, 60 Capsules ($31.30): a plain alpha-lipoic acid product, the ordinary molecule that carries the human trial record discussed above, at a fraction of the complex's cost.
• Amarc Enterprises, Poly-Plus, 8 fl oz (236 ml) ($300.00): an Amarc liquid that pairs Poly-MVA's lipoic acid mineral complex with added vitamin A, and it carries the same evidence caveat set out in this article.

References

1. Sudheesh NP, Ajith TA, Janardhanan KK. Palladium alpha-lipoic acid complex formulation enhances activities of Krebs cycle dehydrogenases and respiratory complexes I-IV in the heart of aged rats. Food and Chemical Toxicology, 2009; 47(8):2124-2128. PMID 19500641
2. Sudheesh NP, Ajith TA, Janardhanan KK. Effect of POLY-MVA, a palladium alpha-lipoic acid complex formulation against declined mitochondrial antioxidant status in the myocardium of aged rats. Food and Chemical Toxicology, 2010; 48(7):1858-1862. PMID 20412826
3. Ajith TA, Nima N, Veena RK, et al. Effect of palladium alpha-lipoic acid complex on energy in the brain mitochondria of aged rats. Alternative Therapies in Health and Medicine, 2014; 20(3):27-35. PMID 24755568
4. Sudheesh NP, Ajith TA, Janardhanan KK. Palladium-alpha-lipoic acid complex attenuates alloxan-induced hyperglycemia and enhances the declined blood antioxidant status in diabetic rats. Journal of Diabetes, 2011; 3(4):293-300. PMID 21679354
5. Antonawich FJ, Fiore SM, Welicky LM. Regulation of ischemic cell death by the lipoic acid-palladium complex, Poly MVA, in gerbils. Experimental Neurology, 2004; 189(1):10-15. PMID 15296831
6. Ramachandran L, Krishnan CV, Nair CK. Radioprotection by alpha-lipoic acid palladium complex formulation (POLY-MVA) in mice. Cancer Biotherapy and Radiopharmaceuticals, 2010; 25(4):395-399. PMID 20701542
7. Sridharan V, Bansal A, Kadirvel R, et al. Late Administration of a Palladium Lipoic Acid Complex (POLY-MVA) Modifies Cardiac Mitochondria but Not Functional or Structural Manifestations of Radiation-Induced Heart Disease in a Rat Model. Radiation Research, 2017; 187(3):361-366. PMID 28231026
8. Veena RK, Ajith TA, Janardhanan KK. Poly-MVA attenuates 7,12-dimethylbenz[a]anthracene initiated and croton oil promoted skin papilloma formation on mice skin. Journal of Experimental Therapeutics and Oncology, 2017; 11(2):125-132. PMID 28976135
9. Veena RK, Ajith TA, Janardhanan KK. Antitumor Effects of Palladium-alpha-Lipoic Acid Complex Formulation as an Adjunct in Radiotherapy. Journal of Environmental Pathology, Toxicology and Oncology, 2016; 35(4):333-342. PMID 27992313
10. Corduneanu O, Chiorcea-Paquim AM, Garnett M, et al. Lipoic acid-palladium complex interaction with DNA, voltammetric and AFM characterization. Talanta, 2009; 77(5):1843-1853. PMID 19159808
11. Selim NS, El-Marakby SM. In-vitro study of the radioprotective effect of palladium alpha-lipoic acid nano-complex on hemoglobin molecule. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2021; 258:119842. PMID 33940572
12. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 1995; 38(12):1425-1433. PMID 8786016
13. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research, 1999; 31(3):171-179. PMID 10499773
14. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care, 1999; 22(8):1296-1301. PMID 10480774
15. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 2006; 29(11):2365-2370. PMID 17065669
16. El-Nahas MR, Elkannishy G, Abdelhafez H, et al. Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study. Endocrine, Metabolic and Immune Disorders Drug Targets, 2020; 20(9):1531-1534. PMID 32370731
17. Teichert J, Kern J, Tritschler HJ, et al. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 1998; 36(12):625-628. PMID 9876998
18. Ikuta N, Okamoto H, Furune T, et al. Bioavailability of an R-alpha-Lipoic Acid/gamma-Cyclodextrin Complex in Healthy Volunteers. International Journal of Molecular Sciences, 2016; 17(6):949. PMID 27314343
19. Brufani M, Figliola R. (R)-alpha-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. Acta Biomedica, 2014; 85(2):108-115. PMID 25245645
20. Rinkovec J. Platinum, palladium, and rhodium in airborne particulate matter. Archives of Industrial Hygiene and Toxicology, 2019; 70(4):224-231. PMID 32623861
21. Wiseman CLS, Zereini F. Airborne particulate matter, platinum group elements and human health: a review of recent evidence. Science of the Total Environment, 2009; 407(8):2493-2500. PMID 19181366
22. Leso V, Iavicoli I. Palladium Nanoparticles: Toxicological Effects and Potential Implications for Occupational Risk Assessment. International Journal of Molecular Sciences, 2018; 19(2):503. PMID 29414923
23. Fromell K, Johansson U, Abadgar S, et al. The effect of airborne Palladium nanoparticles on human lung cells, endothelium and blood: a combinatory approach using three in vitro models. Toxicology In Vitro, 2023; 89:105586. PMID 36931534
24. Forte G, Petrucci F, Bocca B. Metal allergens of growing significance: epidemiology, immunotoxicology, strategies for testing and prevention. Inflammation and Allergy Drug Targets, 2008; 7(3):145-162. PMID 18782021
25. Oleko A, Saoudi A, Zeghnoun A, et al. Exposure of the general French population to metals and metalloids in 2014 to 2016: Results from the Esteban study. Environmental Research, 2024; 252:118744. PMID 38579993
26. Wikipedia. Poly-MVA. Wikipedia, The Free Encyclopedia. Accessed 2026. https://en.wikipedia.org/wiki/Poly-MVA
27. Wikipedia. Lipoic acid. Wikipedia, The Free Encyclopedia. Accessed 2026. https://en.wikipedia.org/wiki/Lipoic_acid

Frequently Asked Questions